Total
Grand Total Score: 23.4 (out of XXXx?)
Grand Total Grade: F
Innovation
Total Score: 31.52%
Grade: D
Canadian Institute of Health Research (CIHR) Funding
IQ1-aWhat percentage of the University’s total CIHR research funding in the last 2 fiscal years is allocated to global health research?
Ans
6.4%
5 (out of 5)
IQ1-b
What percentage of the University’s total CIHR research funding in the last 2 fiscal years is allocated to rare disease research? (rare diseases are defined as any disease, disorder, illness or condition affecting about 40-50/100,000 people)
Ans
4.6%
5 (out of 5)
IQ1-c
What percentage of the University’s total CIHR research funding in the last 2 fiscal years is allocated to neglected disease (ND) research and diseases with neglected aspects including HIV/AIDS, Tuberculosis, Malaria, etc. research?
Ans
0.8%
2 (out of 5)
IQ1-d
What percentage of the University’s total CIHR research funding in the last 2 fiscal years is allocated to emerging infectious disease research?
Ans
2.4%
5 (out of 5)
Noncommunicable Disease Research
IQ2How many noncommunicable diseases (NCD) research grants (or other similar grants that aim to award projects focused on underserved Canadian populations) has the university been awarded in the last 2 calendar years? Please specify the name of each grant received, if multiple were received, and the amount of each.
Ans
0
0 (out of 3)
Publications
IQ3-aWhat percentage of the university's medical PubMed publications in the last 2 calendar years (January 1st, 2019 - December 41s, 2020) are focused on global health?
Ans
2.1%
1 (out of 5)
IQ3-b
What percentage of the university's medical PubMed publications in the last 2 calendar years (January 1st, 2019 - December 41s, 2020) are focused on public health strategy?
Ans
2.7%
1 (out of 5)
IQ3-c
What percentage of the university's medical PubMed publications in the last 2 calendar years (January 1st, 2019 - December 41s, 2020) are focused on neglected diseases, HIV, TB, malaria, antimicrobial resistance, and/or access to medicines in low- and middle-income countries?
Ans
2.1%
1 (out of 5)
IQ3-d
What percentage of the university's medical PubMed publications in the last 2 calendar years (January 1st, 2019 - December 41s, 2020) are focused on indigenous health?
Ans
0.3%
0 (out of 5)
Alternative Models of Biomedical Research
IQ4Is any of the university’s medical research being done in collaboration with, funded by, or driven by alternative models for research and development? (e.g Drug Discovery and Data-Sharing platforms, Prizes, Philanthropy for Drug Discovery, Drug Patent Pools, Public-Private-Partnerships etc.)
Ans
Prize Funding
2 (out of 5)
Global Drug Pricing Research
IQ5Is the University currently engaged in or supporting research on global drug pricing mechanisms to ensure equitable access to affordable medicines, or has research in this area been carried out? Examples of types of initiatives provided.
Ans
No, none of the university's research is being performed in this fashion
0 (out of 5)
Neglected Diseases
IQ7Does the university have, or plan to open, a research center or institute dedicated specifically to neglected diseases, HIV/AIDS, TB, Malaria and/or antimicrobial resistance (AMR)?
Ans
Has a (verified) HIV/AIDS, Tuberculosis, Malaria, or AMR Center
2 (out of 5)
Indigenous Health Research
IQ8Does the university have, or plan to open, a research center or institute dedicated specifically to indigenous medical or health research?
Ans
Responded 0 or failed verification for existing center(s) (0 points)
0 (out of 2)
Access
Total Score: 14.47%
Grade: F
Commitment to Health Access
AQ1-a
Has the university officially and publicly committed to licensing its medical discoveries in ways that promote access and affordability for resource-limited populations? If agreements were agreed upon to promote equitable licensing practices, please name them.
Ans
The university has publicly committed to the general principle of global access licensing, but has not endorsed or disclosed specific strategies for promoting access through licensing; Example: signatories of Stanford’s 2007 Nine Points to Consider in Licensing University Technology:Has the university officially and publicly committed to licensing its medical discoveries in ways that promote access and affordability for resource-limited populations? If agreements were agreed upon to promote equitable licensing practices, please name them.
2 (out of 5)
AQ1-b
Does the website of the university's technology transfer office (TTO) make an effort to disclose, explain and promote access licensing commitments and practices?
Ans
The website offers brief, limited, and non-specific statements on access licensing
1 (out of 5)
Open Access
AQ2
Has the university adopted initiatives or policies supporting open access publications (EXCLUDING STATEMENTS REGARDING COVID-19)?
Ans
Yes, the university has adopted initiatives and/or policies supporting open access publications. However, this support does not fully assist researchers who wish to publish their results in open access sources, for example by not providing funds necessary to publish in an open access journal.
1 (out of 2)
Open Access Publications
AQ3
What percentage of the university's total medical sciences publication output is published in open-access publications?
Ans
45.40%
3 (out of 5)
Non-Exclusive Licensing
AQ4-a
In the past 2 calendar years, what percentage of the university’s total research licenses were non-exclusive? (EXCLUDING COVID-19 RELATED LICENSES)
Ans
No Data
0 (out of 5)
AQ4-b
In the past 2 calendar years, what percentage of the university’s health technology licenses were non-exclusive?
Ans
No Data
0 (out of 5)
LMIC Patents
AQ5-a
In the past 2 calendar years, for what percentage of all health technologies did the university seek patents in low- and lower-middle-income countries as defined by the World Bank?
Ans
No Data
0 (out of 5)
AQ5-b
In the past 2 calendar years, for what percentage of all health technologies did the university seek patents in upper-middle-income countries as defined by the World Bank?
Ans
No Data
0 (out of 5)
Access to Research
AQ6-aIn the past 2 calendar years, what percentage of the university’s exclusive licenses of health technologies included provisions to promote access to those technologies in low- and middle-income countries as defined by the World Bank?
Ans
No Data
0 (out of 5)
AQ6-b
In the past 2 calendar years, what percentage of the university’s exclusive licenses of health technologies included provisions to promote access to those technologies in high-income countries as defined by the World Bank?
Ans
No Data
0 (out of 5)
Best Practices
AQ7-aHas the university shared its best practices for promoting access to medicines through licensing in the past 2 calendar years?
Ans
No
0 (out of 5)
Alternative Research and Development Models
AQ8-aHas the university publicly stated the existence/effectiveness of alternative models of research and development as being important to ensuring access to medical innovation?
Ans
Published an article on alternative research and development
2 (out of 5)
Patent Pools
AQ9-aHas the university submitted a patent(s) recently (after 2010) to the Medicines Patent Pool (MPP) or World Intellectual Property Organization (WIPO) for protected intellectual property status for medicines treating HIV, hepatitis C, malaria, tuberculosis, neglected diseases, or other patented essential medicines in low- and middle-income countries?
Ans
No
0 (out of 1)
Empowerment
Total Score: 18.92%
Grade: F
Global Health Education
EQ1-aDoes the university offer its students access to global health engagement and/or education? [As indicated by the existence of a university center/institute, department, and/or non-degree program in global health.]
Ans
Global health department/ office
2 (out of 5)
EQ1-b
Does the university offer its students access to global health engagement and/or education? [As indicated by the existence of a university center/institute, department, and/or non-degree program in global health.]
Ans
No, the university does not offer its students any of these oppurtuniites
0 (out of 5)
EQ2
EQ2-aDid the university offer courses in the last 2 academic years that address the policy and legal context of biomedical R&D, and more specifically the impact of intellectual property policies, on research priorities and global access to medical innovations?
Ans
No
0 (out of 2)
EQ2-ab
Is/are the course(s) required for any major programs?
0 (out of 1)
EQ2-b
Did the university offer courses in the last 2 academic years that address the prevalence of and/or lack of research on neglected diseases, including neglected aspects HIV, TB, and/or malaria?
Ans
No courses offered
0 (out of 2)
EQ2-bb
Is/are the course(s) required for any major programs?
Ans
No
0 (out of 1)
EQ2-c
Did the university training opportunities (courses, conferences, seminars, etc.) for students and faculty on cultural sensitivity and/or decolonized approaches to global health?
Ans
No courses offered
0 (out of 2)
EQ2-cb
Is/are the course(s) required for any major programs?
Ans
No
0 (out of 1)
Indigenous Engagement
EQ3Does the university have programs to maximize Indigenous student enrollment in health related programs? If applicable, please describe the program.
Ans
Yes
1 (out of 1)
Conference or Convening
EQ4Has the university hosted a major (in person or remote) conference, symposium or campus-wide event in the past 2 academic years on: Part A: The policy and legal context of biomedical R&D, specifically the impact of intellectual property rights on research priorities and global access to medical innovations? If the university has hosted multiple events for this category, please specify how many; Part B: Neglected diseases, HIV, TB, and/or malaria, and health needs of low- and middle-income countries? If the university has hosted multiple events for this category, please specify how many; Part C: Promoting drug access for low income populations in high income countries? If the university has hosted multiple events for this category, please specify how many.
Ans
No - no events
0 (out of 5)
Global Partnerships
EQ5Is the university formally involved in a global health partnership with one or more universities based in low- and middle-income countries?
Ans
Yes, partnership exists
1 (out of 1)
Learning about Alternative R&D
EQ6Does the university offer any of its students an opportunity to learn more about alternative models for research and development through courses, workshops, or other opportunities?
Ans
No opportunities offered
0 (out of 1.5)
Transparency
Total Score: 29.27%
Grade: D-
Responsiveness
TQ1How responsive was the university's Technology Transfer Office (TTO) to emails from UAEM regarding the section surveys?
Ans
No response received throughout entire Data Collection period
0 (out of 2)
Access data in the Public Domain
TQ2-a
For questions relying on public data (CATEGORY 1) in the Access section, was sufficient information available in public sources/databases?
Ans
Yes
4 (out of 4)
TQ2-b
For questions relying on public data (CATEGORY 1) in the Innovation section, was sufficient information available in public sources/databases?
Ans
Yes
4 (out of 4)
TQ2-c
For questions relying on public data (CATEGORY 1) in the Empowerment section, was sufficient information available in public sources/databases?
Ans
Yes
4 (out of 4)
TQ2-e
For questions relying on public data (CATEGORY 1) in the COVID-19 section, was sufficient information available in public sources/databases?
Ans
Yes
4 (out of 4)
Discrepancies
TQ3How much discrepancy exists between university responses in the submitted forms and what is being internally collected using publicly available data for Category 1 and 2 questions?
Ans
University did not submit forms
0 (out of 4)
Clinical Trial Data Transparency
TQ4-a/bWhat percent of all of the university’s clinical trial data was published during the last 2 calendar years?
Ans
0%
0 (out of 5)
Publishing Clinical Trial Data
TQ5In the past 4 calendar years, what percentage of completed clinical trials conducted by the university and registered on ClinicalTrials.gov had their data shared as summary results on ClinicalTrials.gov or PubMed?
Ans
0%
0 (out of 5)
Clinical Trial Policy
TQ6Does the university have policies that mandate that all university researchers publish all results of all clinical trials? Y/N. If so, please provide the university’s policy or examples of the university’s policy.
Ans
No
0 (out of 1)
Prospective Registration
TQ7Do you recommend or require your researchers to prospectively register all clinical trials with an appropriate registry before any subject is enrolled?
Ans
Yes, the university requires researchers to prospectively register clinical trials with an appropriate registry before any subject is enrolled for all of university clinical trials
2 (out of 2)
Public Acknowledgement: Clinical Trials
TQ8Does the university publicly acknowledge the need to be transparent in clinical trial results? If yes, check all that apply.
Ans
No, the university does not publicly acknowledge the need to be transparent in clinical trial results
0 (out of 2)
Private Companies' Involvement in Clinical Trials
TQ9-aDoes the university engage in commissioned research from private companies? Y/N
Ans
No
TQ9-b
Do these companies have the ability to insert clauses affecting or preventing data publication? Y/N
Ans
N/A
2 (out of 2)
Conflict of Interest
TQ10-aDoes the university have clear guidelines, or policies, for conflict of interest regarding partnerships with industry with a potential for commercial interest?
Ans
Yes, there are clear guidelines for conflict of interest in situations regarding partnerships with industry with a potential for commercial interest. (1 point)
1 (out of 2)
Covid19
Total Score: 20.83%
Grade: F
CQ2-a
CQ2Has the University signed on to the Open Covid Pledge or signed a similar agreement regarding intellectual property for the COVID-19 pandemic? Please specify which agreement the university is a signatory for.
Ans
No response
0 (out of 3)
CQ3
CQ3Has the University made agreements on COVID-19 research/technology licensing with private companies? If yes, is the license exclusive or non-exclusive? If possible, please provide sample language from the licensing agreement.
Ans
97%
5 (out of 2)
CQ4
CQ4What percentage of the University’s publications on COVID-19 biomedical research are available open access (from March 2020 - March 2021)?
Ans
No - no events
0 (out of 5)
CQ5
CQ5-aHas the university hosted a (remote) conference, symposium or event in the last 12 months on COVID-19 needs of low- and middle-income countries?
0 (out of 3)
CQ5-b
Has the university hosted a (remote) major conference, symposium, or event in the last 12 months on biomedical COVID-19 related challenges/solutions for populations with historically low access to medicines, including Indigenous communities, within high-income countries such as Canada and the United States?
Ans
No response
0 (out of 3)
CQ6
CQ6-aHas the University translated its COVID-19 public health strategy research findings into practical resources that are available and accessible to indigenous communities? If yes, please provide examples.
CQ6-b
